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Genotyping of important medical or veterinary prokar-
yotes has become a very important tool during the last 
decades. Rapid development of fragment-separation 
and sequencing technologies has made many new 
genotyping strategies possible. Among these new 
methods is multilocus variable-number tandem repeat 
analysis (MLVA). Here we present an update on the use 
of MLVA in eight European countries (Denmark, France, 
Germany, Ireland, Italy, the Netherlands, Norway and 
Sweden). Researchers in Europe have been active in 
developing and implementing a large array of different 
assays. MLVA has been used as a typing tool in several 
contexts, from aiding in resolving outbreaks of food-
borne bacteria to typing organisms that may pose a 
bioterrorist threat, as well as in scientific studies. 
Introduction
Multilocus variable-number tandem repeat analysis 
(MLVA) is a DNA-based molecular typing method fre-
quently applied to the study of prokaryotes. It records 
size polymorphisms in several variable-number of tan-
dem repeats (VNTR) loci amplified by stringent PCR 
protocols. MLVA will mainly impact the public health 
field by introducing newer, faster and safer (reduced 
handling of live bacteria) methodologies for typing 
microorganisms. Reduced typing time, with high reso-
lution, is beneficial for resolving large and complex 
outbreak situations. The methodology is also suitable 
for large-scale automation: suitable instruments (e.g. 
automated sequencers, pipetting robots and analytical 
software) are already commercially available. There are 
several variations of MLVA assays depending on avail-
able instrumentation. Earlier versions tended to meas-
ure VNTR sizes by agarose gel electrophoresis, while 
newer assays often use capillary electrophoresis for 
size determination once the allele size range at each 
locus has been well characterised. 
As mentioned above, MLVA assays have clear advan-
tages, offering fast typing, high resolution and reduced 
handling times of pathogenic organisms. Their draw-
backs include high assay-specificity (e.g. each organ-
ism usually needs a distinct MLVA assay) and the, as 
yet, lack of standardisation for the majority of published 
assays. In Europe, only the Salmonella enterica sub-
species enterica serovar Typhimurium (S. Typhimurium) 
MLVA assay has achieved generally accepted stand-
ardisation [1,2]. MLVA is gaining in popularity: in 2000, 
there was only one PubMed entry (when searching for 
‘MLVA’) while in 2011, there were 96 entries for articles 
that year alone. There has been extensive research on 
MLVA and MLVA protocol development within Europe: 
an overview of organisms for which there are exist-
ing MLVA assays in European countries, based on web 
searches for protocols is presented in Table 1. The web 
searches were performed on 23 April 2012 and repeated 
on 18 June in PubMed using the search terms; ‘MLVA’, 
‘VNTR’, ‘tandem repeats’, ‘TR’, ‘direct repeats’, ‘DR’ and 
‘genotyping’, combined with geographical names such 
as ‘Europe’, ‘European’ or the countries within Europe. 
General Internet searches using the same keywords in 
a standard web browser were also included. The same 
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searches were also repeated using Google Scholar and 
the Scirus search engine.  
In this Euroroundup, we present a more in-depth 
update on the use of MLVA in eight European countries. 
European researchers with publications describing the 
development or use of MLVA assays were contacted: 
those who chose to contribute to this Euroroundup 
were included. The authors were given a choice of writ-
ing a general overview of MLVA assays used in their 
respective countries and/or giving examples where 
MLVA has been used to improve public health, e.g. by 
aiding in solving outbreaks. 
Denmark
In Denmark, culture-confirmed cases of Salmonella 
and Listeria infection are notifiable by clinical labora-
tories to the Statens Serum Institut (SSI). Furthermore, 
all isolates are routinely sent to SSI from the local clini-
cal departments and are included in the national sur-
veillance data. All Listeria isolates and the two main 
serotypes of Salmonella – S. Typhimurium (including 
the monophasic variant) 4,[5],12:i:- and Salmonella 
enterica subspecies enterica serovar Enteritidis (S. 
Enteritidis) – are real-time typed using MLVA in order 
to investigate clusters and detect outbreaks. 
All incoming S. Typhimurium isolates have been typed 
by MLVA [1] at SSI since 2003 and all MLVA fragments 
are converted to true allele numbers using the refer-
ence collection and standardised MLVA method [2]. As 
of April 2012, a total of 6,118 S. Typhimurium isolates 
had been MLVA typed for routine surveillance and sep-
arated into 1,102 different MLVA types. Several clusters 
have been investigated in this period [3] and the imple-
mentation of MLVA has helped to define and solve both 
national and international outbreaks [4]. MLVA has fur-
thermore been used for typing of food, feed and animal 
isolates, enhancing our ability to identify the source of 
a food-borne outbreak. 
Three MLVA types (2-11-13-9-212, 2-15-7-10-212 and 
3-20-7-6-212) accounted for more than 28% of all iso-
lates in Denmark and were seen in an outbreak that 
lasted over two years (2008–2009) and included more 
than 1,700 patients [5]. The limited number of geno-
types identified was not due to a lack of discrimination 
using MLVA or indeed pulsed-field gel electropho-
resis (PFGE) or phage typing: all three methods were 
applied during this outbreak, which was unfortunately 
never solved. Several isolates from the entire period 
that this outbreak took place have undergone whole 
genome shotgun sequencing: very few single nucleo-
tide polymorphisms (SNPs) are present in these three 
MLVA types. These data will be presented in a later 
manuscript.
Another group, accounting for 13% of all S. Typhimurium 
isolates, is comprised of five closely related MLVA types 
that have been predominant from 2005 and still are 
(the five types are the constant loci STTR9 (3), STTR10 
(NA) and STTR3 (211) and different combinations of the 
variable loci STTR5 (11,12,13) and STTR6 (9,10), where 
paranthesised numbers denote allele sizes and NA (no 
amplification) indicates negative PCR amplification, as 
previously described [2].
MLVA typing of S. Enteritidis has been carried out for 
routine surveillance since 2009 [6] and all MLVA frag-
ments are converted to true allele numbers using the 
reference collection and five standardised loci [7]. By 
April 2012, a total of 1,371 S. Enteritidis isolates had 
been MLVA typed and divided into 131 different MLVA 
types. The Danish routine surveillance MLVA data have 
been used in defining clusters and linking patients 
with an S. Enteritidis infection to a common source or 
event. A high percentage of S. Enteritidis infections 
in Denmark are acquired abroad and MLVA typing of 
S. Enteritidis could be of added value when trying to 
define and solve international outbreaks in the future. 
Two groups of MLVA types account for more than half 
of all S. Enteritidis isolates. One group, seen in 33% of 
isolates, consists of three MLVA types with four loci in 
common – SE1 (3), SE2 (7), SE9 (2) and SE3 (4) – and 
one variable locus, SE5 (10, 12 or 13). Two MLVA types 
make up 25% and have four loci in common – SE1 (4), 
SE2 (5), SE9 (3) and SE3 (3) – and one variable locus, 
SE5 (9 or 10). 
For molecular surveillance of Listeria infections, SSI 
uses an in-house developed MLVA method that has 
shown promise in cluster detection and outbreak inves-
tigations. The method is still being validated in our lab-
oratory by comparing MLVA data with those from PFGE. 
France
French researchers have been very active for more 
than 10 years in developing MLVA for the genotyping 
of pathogenic bacteria and fungi of global health inter-
est (concerning humans, animals and plants) or which 
may pose a bioterrorist threat. These developments 
have included the setting up of new assays and of tools 
accessible on the Internet to facilitate the development 
of such assays [8]. Of particular interest are online 
databases presenting MLVA typing data, including the 
first one, made public in 2002 [8], the development 
and commercialisation of typing kits and the provision 
of typing services. MLVA is currently in the phase of 
entering routine practice in a number of reference labo-
ratories and a market seems to be emerging in France.
MLVA is primarily used in France for six bacterial 
species of high medical interest. The MLVA used for 
Mycobacterium tuberculosis [9] is now well-known 
worldwide as mycobacterial interspersed repetitive 
units- variable-number tandem repeat (MIRU-VNTR), 
owing to the efforts of a company (Genoscreen, Lille, 
France) in Institut Pasteur Lille and to the importance 
of this pathogen. This assay has also served as a 
pilot for the development of large-scale MLVA typing 
and associated databases. More recently, MLVA has 
been developed for Staphylococcus aureus, Legionella 
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pneumophila and Pseudomonas aeruginosa, with the 
production of fully automated assays and of typing kits 
by the Centre Européen d’Expertise et de Recherche 
sur les Agents Microbiens (CEERAM) at La Chapelle 
sur Erdre. In the L. pneumophila assay, 12 loci are co-
amplified in a single multiplex PCR [10]. Alternatively, 
the assays can be set up locally, with no need to buy 
kits, since all the necessary information is published 
[10-12]. MLVA is also in routine use for Streptococcus 
pneumoniae, with more than 1,000 genotypes publicly 
accessible from the the Robert Picqué Military Hospital 
in Bordeaux [13] and for Acinetobacter baumanii [14].
An MLVA assay for Streptococcus agalactiae has also 
been developed in France and additional MLVA assays 
are currently being developed by the Agence nation-
ale de sécurité sanitaire de l’alimentation (ANSES) 
for zoonotic agents and by the Centre de coopéra-
tion internationale en recherche agronomique pour le 
développement (CIRAD) for plant pathogens.
MLVA assays, which are now used worldwide, have also 
been developed for major bioterrorist agents, includ-
ing Yersinia pestis and Bacillus anthracis [15], as well 
as minor agents, such as Brucella spp. [16], together 
with associated online databases.
Four web-based MLVA databases have been developed 
in France. The first [17], hosted by Université Paris 
Sud in Orsay, and used worldwide, started in 2002. 
The third version was released in 2007 and a fourth, 
which will be able to manage a variety of sequence-
based assays in addition to MLVA, is currently under 
development. The second database [13], developed by 
the Robert Picqué Military Hospital, was released in 
2007. Importantly these two websites allow external 
users to create their own database, with user-defined 
species, set of loci, etc., independently of the host-
ing institution. The resulting databases can be shared 
within a community or even made publicly accessible. 
The other two MLVA databases were developed by the 
Institut Pasteur in Paris [18] and Guadeloupe [19]; the 
latter is dedicated to M. tuberculosis. A list of websites 
hosting MLVA genotyping databases for a number of 
pathogens is maintained at the genomes and polymor-
phisms website [8].
A number of French national or regional reference labo-
ratories are now shifting to, or at least evaluating MLVA 
as a first-line typing tool: this is the case, for instance, 
for the A. baumanii, Burkholderia, L. pneumophila and 
S. aureus reference laboratories. 
The following section focuses on the use of MLVA for 
enteropathogenic bacteria genotyping in France.  
Use of MLVA for enteric pathogens
In France, laboratory-based approaches are a key com-
ponent of monitoring strategies for enteric pathogens, 
as a voluntary laboratory-based network of clinical 
and veterinary laboratories send bacterial isolates to 
the National Reference Centre (NRC), which performs 
serotyping analysis and runs weekly outbreak detec-
tion algorithms [20]. The basic information currently 
provided by French laboratories to public health sur-
veillance is the serotype of isolates; however, the 
discriminatory capacity is limited. Only a few sero-
types are highly prevalent worldwide: Typhimurium 
and Enteritidis for Salmonella, sonnei for Shigella and 
O157 for enterohaemorrhagic Escherichia coli (EHEC). 
Differentiation between isolates of the most common 
serotypes requires the use of subtyping methods: in 
France, this is carried out by the national reference 
centres or national veterinary laboratories.  
Standardised MLVA schemes for two Salmonella sero-
types, Typhimurium and Enteritidis, have been used 
in France since 2005 and 2006, respectively [2,7]. 
For S. Typhimurium and its monophasic variant, the 
most common Salmonella serotypes identified in 
France from humans and non-humans, the reference 
laboratories use the widely accepted MLVA nomen-
clature [2]. Due to a high number of Typhimurium and 
4,[5],12:i:- strains collected from humans by the French 
National Reference Centre annually – around 4,000 
and 1,000 respectively [21] – MLVA is exclusively used 
for outbreak investigations to complement primarily 
molecular subtyping, i.e. PFGE or clustered regularly 
interspaced short palindromic repeats (CRISPR) analy-
sis. MLVA is particularly performed to compare strains 
with those notified from an outbreak in other European 
countries or to discriminate among clonal isolates 
indistinguishable by PFGE or CRISPR analysis, such as 
those belonging to the multidrug-resistant DT104 sero-
type Typhimurium population or to the egg-related PT4 
Enteritidis.  A total of 1,252 Salmonella clinical isolates 
were tested by MLVA in France from 2005 to 2011. Of 
879 S. Typhimurium strains, there were 380 profiles; 
of 373 monophasic variant strains, there were 40 pro-
files, suggesting that the 4,[5],12:i:-clone has emerged 
recently. 
Shigella sonnei is a monomorphic organism and 
therefore requires a highly discriminative sequence-
based method for investigations. In France, S. sonnei 
outbreaks have been described and some have been 
investigated using an eight-loci MLVA scheme with a 
good Simpson diversity value, as previously described 
[22].  
For E. coli O157, MLVA is not performed routinely, as 
PFGE is sufficient for tracking outbreaks, but it could 
be used for characterisation of an epidemic clone. 
Germany
At the National Reference Laboratory for the Analysis 
and Testing of Zoonoses (Salmonella) in Berlin, MLVA is 
applied for outbreak studies involving S.Typhimurium, 
monophasic S.Typhimurium and S. Enteritidis. For 
S. Typhimurium, the standardised protocol [1,2] is used 
and for S. Enteritidis, the method published by Malorny 
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et al. [23] is used. The reference laboratory performs 
about 10 outbreak and tracing studies per year.
S.Typhimurium surveillance in Germany relies initially 
on phage typing. At the National Reference Center for 
Salmonella and other Enterics in Wernigerode, each 
year, about 200 to 300 human clinical S. Typhimurium 
isolates from a large sentinel region (five federal states 
in the middle and west of Germany) are phage typed 
and kept in a strain collection. Over the past five years, 
30% to 10% (decreasing annually) of these isolates 
were of phage type DT104. However, in March and 
April 2010, 38 (49%) of all 77 S. Typhimurium isolates 
obtained from this region were of phage type DT104. 
Strikingly, 34 of these DT104 isolates revealed resist-
ance to nalidixic acid, in contrast to none of the six 
DT104 isolates from January and February that year. 
Moreover, all of the 74 S. Typhimurium isolates with 
nine different non-DT104 phage types obtained from the 
sentinel region between January and April 2010 were 
susceptible to nalidixic acid. The most obvious expla-
nation for such a substantial increase in the number of 
S. Typhimurium isolates with the phenotypic-character 
combination of phage type DT104 and nalidixic acid 
resistance would be a local outbreak. Here we outline 
hitherto unpublished data on how MLVA was used to 
identify the outbreak clone.
Searching for a potential source of the infec-
tions, regional public health authorities isolated S. 
Typhimurium from several food samples from within 
the sentinel region; among these were DT104 isolates 
from pork carcasses and from raw sausages, made 
in a butcher’s shop as a regional delicacy. The DT104 
isolates from the carcasses were not resistant to nali-
dixic acid, but those from the sausages were. We sub-
jected all clinical and food DT104 isolates obtained 
from January to April 2010 from the sentinel region to 
MLVA analysis. In addition, we included several pheno-
typically similar isolates from sporadic cases obtained 
during the same period from geographically distant 
regions of Germany. The MLVA results are summarised 
in Table 2. 
Identical MLVA patterns were observed among the 
majority of clinical S. Typhimurium DT104 isolates 
resistant to nalidixic acid and the raw-sausage isolates 
(Table 2, rows 1 and 4). It is interesting to note that in 
two phenotypically indistinguishable isolates there 
were single locus allelic variants (Table 2, rows 2 and 
Table 2
MLVA analysis of Salmonella enterica subspecies enterica serovar Typhimurium phage type DT104 strains, Germany, 
January–April 2010 (n=44)
Row number Source of S. Typhimurium  DT104 isolates Month of isolation Antiobiotic resistance
a Allele string of VNTR loci
Isolates from the sentinel region
1 29 cases Mar–Apr A, C, T, S, Su, Nal 3-14- 9-19-311
2 1 case Mar A, C, T, S, Su, Nal 3-14-10-19-311
3 1 case Mar A, C, T, S, Su, Nal 3-14- 9-20-311
4 1 isolate (raw sausage) Mar A, C, T, S, Su, Nal 3-14- 9-19-311
5 1 isolate (pork) Mar A, C, T, S, Su 3-13-14-16-111
6 1 isolate (pork) Mar A, C, T, S, Su 3-14-14-16-111
7 1 case Feb A, C, T, S, Su 3-14- 3-20-311
8 1 case Jan A, C, T, S, Su 3-13- 5-12-311
9 2 cases Jan A, C, T, S, Su 3-17-12-16-111
Phenotypically similar isolates from geographically distant regions of Germany
10 1 case Jan A, C, T, S, Su, Nal 3-16- 3-23-311
11 1 case Jan A, C, T, S, Su, Nal 3-10-20-12-311
12 1 case Feb A, C, T, S, Su, Nal 3-14-18-23-311
13 1 case Mar A, C, T, S, Su, Nal 3-14- 9-19-311
14 1 case Mar A, C, T, S, Su 3-13- 5-12-311
15 1 case Apr A, C, T, S, Su, Nal 3-12-14-16-311
A: ampicillin; C:chloramphenicol; MLVA: multilocus variable-number tandem repeat analysis; Nal: nalidixic acid; S: streptomycin; Su: 
sulphonamide; T: (oxy)tetracycline; VNTR: variable-number tandem repeat.
a  Based on antibiogram results. Antibiotic susceptibility testing was performed by broth microdilution method [24]. Breakpoints for 
interpretation of minimum inhibitory concentration (MIC) values were derived from the European Committee on Antimicrobial Susceptibility 
Testing (EUCAST) epidemiological cut-off values [25].
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3), affecting the loci STTR6 and STTR10, respectively. 
In each case, one locus differed by the presence of one 
additional repeat unit at the respective VNTR site, com-
pared with the outbreak strain MLVA pattern (Table 2, 
row 1). Therefore, these loci might well be hypervari-
able, i.e. drifting towards diversity even within a given 
outbreak. Attention must be paid to such possible 
hypervariability, particularly when attempting to use 
MLVA for long-term surveillance. The phenotypically 
indistinguishable but spatially and/or temporally inde-
pendent S. Typhimurium isolates, however, (Table 2, 
rows 5 to 15) were clearly distinguishable by the MLVA 
approach used.
Ireland
MLVA is used in Ireland for Salmonella subtyping: at 
the National Reference Laboratory (NRL) for Salmonella 
in County Kildare, its use is related to food, animal 
feed and animal health; MLVA subtyping for pub-
lic health is carried out at the National Salmonella 
Reference Laboratory, Galway. All Salmonella strains 
isolated from official and food business operator con-
trol programmes are submitted to the NRL for typing 
and this provides an accurate picture of the diversity 
of Salmonella strains circulating in Ireland. Although 
S. Enteritidis and S. Typhimurium are virtually absent 
in poultry production due to a stamp out policy, 
S. Typhimurium, including the monophasic variant, is 
frequently isolated largely due to targeted sampling 
in the pig sector, where the serotype is prevalent. S. 
Typhimurium is also frequently isolated from samples 
of bovine or equine origin. More extensive information 
can be found in the 2011 annual report from the NRL for 
Salmonella in food, feed and animal health [26]. 
The NRL for Salmonella uses the standardised MLVA 
assay [1,2]. This method was initially set up in 2009 
using the MegaBACE 1000 but since 2011, it has been 
based on the ABI 3500 platform. MLVA is applied to 
ascertain epidemiological linkages between isolates 
from different sources, e.g. to investigate transmission 
through the food chain or to prove cross-contamina-
tion in specific settings. It has also been very useful 
to characterise strains related to outbreaks. One such 
outbreak began in the autumn of 2009 and continued 
into 2010: the outbreak strain was clearly identified 
by its distinctive phage type, DT8, and by being fully 
susceptible to antimicrobials [27]. The MLVA pattern 
was observed to be either 2-9-NA-12-0212 or 2-10-NA-
12-0212. Reported consumption of or exposure to duck 
eggs explained 70% of cases. Trace-back investiga-
tions identified S. Typhimurium DT8 with indistinguish-
able MLVA types from several egg-laying duck flocks. 
Controls have been introduced in duck egg production 
units and testing has continued, which has demon-
strated S. Typhimurium DT8 in over 30 sites (unpub-
lished data). 
Another example of the use of MLVA is the retrospec-
tive study that was conducted to characterise por-
cine S. Typhimurium isolates recovered from different 
points in the food chain, from farms to meat process-
ing establishments [28]. It compared the effectiveness 
of MLVA, phage typing and antimicrobial susceptibility 
testing in discriminating isolates for epidemiological 
purposes. From 301 isolates, 154 MLVA patterns were 
obtained, compared with 19 phage types and 38 anti-
microbial resistance patterns. MLVA was particularly 
useful for discriminating between isolates of the same 
or similar phage type, e.g. DT104 and DT104b, or iso-
lates that were untypable or in the category of ‘reacts 
with phage but does not conform to a recognised 
phage type’ (RDNC) by phage typing. Cluster analysis 
of MLVA profiles demonstrated two major clusters (I 
and II), which had a clear association with particular 
phage types: cluster I isolates were associated with 
phage types DT104, U302 and DT120; cluster II with 
DT193 and U288. The study showed that MLVA was 
highly discriminatory and permitted the identification 
of indistinguishable profiles among isolates obtained 
at different points of the pork food chain.
Italy
Brucellosis is an important zoonosis caused by mem-
bers of the genus Brucella, which is endemic in the 
south of Italy, and in particular in Sicily. In addition, 
Brucella spp. represent potential biological warfare 
agents. Since 1995, the availability of whole genome 
sequences has enhanced the development of multi-
locus VNTR-based typing approaches such as MLVA. 
In 2006, a scheme called MLVA-15 – based on a sub-
set of 15 loci that comprises eight markers with good 
species-identification capability and seven with higher 
discriminatory power – was published [29], followed 
by MLVA-16, a slight modification of MLVA-15 [16]. 
The MLVA band profiles obtained can be resolved 
by techniques such as agarose gel electrophoresis, 
microfluidics technology and DNA sequencing. The 
Dipartimento Sanità Pubblica Veterinaria e Sicurezza 
Alimentare (Department of Veterinary Public Health 
and Food Safety) of the national public health institute, 
Istituto Superiore di Sanità, performs MLVA-15 by direct 
sequencing of the PCR fragments [30]. The molecular 
biology section, Centro Studi e Ricerche di Sanità e 
Veterinaria (CSRSV), of the Italian Army developed a 
high-throughput system of MLVA-15 and -16 typing for 
Brucella spp. using ‘lab-on-a-chip’ technology [31,32]. 
Furthermore, the CSRSV and the National Reference 
Center for Brucellosis in Italy, Istituto Zooprofilattico 
Sperimentale dell’Abruzzo e del Molise Giuseppe 
Caporale, are developing a new high-throughput 
Brucella genotyping system based on capillary gel 
electrophoresis. 
Human anthrax is currently rare in Italy, the last case 
was reported in 2006 [33], while for fatal cases, only 27 
were reported from 1969 to 1997 [34,35]. Animal cases 
are mainly located in central and southern Italy, where 
anthrax is still enzootic, as in other Mediterranean 
areas. The Centro Studi e Ricerche di Sanità e 
Veterinaria (CSRSV) has developed the most discrimi-
natory MLVA-based method for subtyping Bacillus 
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anthracis [15], worldwideadopted, based on the analy-
sis of 25 VNTR markers on an automated platform. In 
2006, 73 Italian B. anthracis samples were typed by 
this method, showing that most of the Italian strains 
were located in the A1.a group, but some strains iso-
lated in northern Italy belonged to B or D groups. This 
result was an important novelty compared with previ-
ous data published in 2005 [36], in which MLVA analy-
sis of 64 Italian isolates revealed that the majority of 
strains (63/64) belonged to the genetic cluster A1.a, 
while one isolate was associated with the A3.b cluster. 
A more recent report (2011) confirmed that in northern 
Italy strains belonging to the B group could be isolated 
[37]. This B lineage is present in Italy, the French Alps, 
Germany and Croatia, so it could be assumed that B 
genotypes persist in livestock in the French and Italian 
Alps.
Clostridium botulinum, the etiological agent of botu-
lism, caused in Italy between 2006 and 2011 about 
137 botulism cases, one of the highest prevalences 
in Europe [38]. The reference centre for botulism in 
Italy is the Centro Nazionale di Riferimento per il botu-
lismo (CNRB), which is part of the Istituto Superiore di 
Sanità. CNRB maintains a collection of more than 400 
Clostridium botulinum strains, characterised by pheno-
typic as well as and genotypic approaches. At CSRSV, 
a MLVA-15 research project has been developed for 
C. botulinum in collaboration with laboratories of 
the other countries participating in the European 
Biodefence Laboratory Network (EBLN). Strains were 
provided mainly by the CNRB and also by other EBLN 
institutions. This MLVA scheme improved the dis-
criminatory power compared with the previous MLVA-
10 scheme for C. botulinum [39]. The analysis was 
extended to B and F toxin serotype strains, in addition 
to A serotype strains: five newly characterised MLVA 
loci were added to the previous 10-MLVA scheme and 
new groups were described. To date, MLVA data have 
been obtained for about 300 international C. botuli-
num strains, whereas   profiles from 79 strains across 
Europe have been published [40].
The Netherlands
In the Netherlands, MLVA is used to characterise sev-
eral pathogenic bacterial species, in research set-
tings and for surveillance purposes. The molecular 
typing profiles are used to study transmission routes 
and assess sources of infection and also to assess 
the impact of human intervention, such as vaccination 
and use of antibiotics on the composition of bacterial 
populations. MLVA schemes have been developed and 
used by several groups outside the National Institute 
for Public Health and the Environment (RIVM) for the 
typing of several pathogens, e.g. vancomycin-resistant 
enterococci [41] and gonococci [42]. 
Within RIVM, several MLVA schemes have been devel-
oped, which are currently used for surveillance of, 
for example, meticillin-resistant S. aureus (MRSA), 
S. pneumoniae, Bordetella pertussis, Haemophilus 
influenzae serotype b and Neisseria meningitidis. In 
addition, the national reference laboratory for tuber-
culosis, located within RIVM, uses the MIRU typing 
assay (24-loci MLVA) for M. tuberculosis. The MLVA 
schemes developed at RIVM and a typing tool for these 
pathogens are maintained at RIVM [43]. The typing tool 
allows interrogation of a MLVA-type table:  by typing 
in an MLVA allelic profile, it will report both the MLVA 
type and MLVA complex. The tool can be set to report 
the exact and closest matching profiles. 
MLVA of MRSA is by far the most intensely used MLVA 
scheme in RIVM. By May 2012, the MRSA MLVA data-
base contained MLVA profiles of nearly 29,000 isolates 
and 3,351 different profiles and 28 MLVA complexes 
were recognised among these isolates. For MRSA, vir-
tually all isolates are sent to RIVM for molecular typing 
as part of the national MRSA surveillance. The S. pneu-
moniae database is the second largest MLVA database 
at RIVM. Although smaller, it still contains profiles of 
approximately 4,000 isolates.
In all MLVA schemes used in RIVM, assessment of the 
number of repeats in each locus is performed by siz-
ing of the fluorescently labelled PCR products on an 
automated DNA sequencer. Each unique MLVA profile 
is given a MLVA type designation, e.g. MT21, and pro-
files are used for clustering and assignment of MLVA 
complexes. The use of fluorescent labels also allows 
for the simultaneous MLVA and detection of particular 
genes. This was used in the MRSA MLVA protocol, in 
which primer sets were included to detect the mecA 
and lukF genes.
Although separation of the PCR products is performed 
on a DNA sequencer, standardisation may pose a prob-
lem for MLVA. Differences may be caused by the use 
of different sequencers, buffers, etc. In order to com-
pensate for these effects, RIVM supplies calibration 
sets (shipping costs only) that contain mixtures of PCR 
products of all known alleles for a particular scheme. 
Such a calibration set will reveal the positions to which 
the alleles will migrate on the user’s sequencer and 
will help to define the correct bin positions.
Norway
In Norway, the Norwegian Institute of Public Health 
(NIPH) is the primary facility for nationwide surveil-
lance of food-borne infections. MLVA is used exten-
sively as the primary routine genotyping tool for a 
number of enteropathogenic bacteria with the excep-
tion of Campylobacter spp. (for which other methods 
are applied), giving the NIPH an up-to-date overview 
of the spread and introduction of these pathogens in 
Norway. NIPH genotypes and maintains databases for 
E. coli, S. Typhimurium, Shigella spp. Yersinia entero-
colitica and Listeria monocytogenes. For typing E. coli, 
three different protocols are in use: two designed for 
E. coli O157:H7 and sorbitol-fermenting O157:H- strains 
(unpublished), as well as a generic MLVA assay able to 
genotype all serotypes of E. coli using 10 loci [44]. In 
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2011, 509 E. coli isolates were routinely typed using the 
generic E. coli MLVA assay, giving rise to 348 distinct 
genotypes, with no major outbreaks detected. 
The MLVA assays have proven to be highly valuable in 
strain surveillance and outbreak detection in Norway. 
It is the speed and resolution of MLVA in particular 
that has made it the primary genotyping method at 
NIPH. MLVA data are further coupled with data from 
virulence-gene assays, phylogenetic-group typing, 
antibiotic resistance data (if available) or other typing 
methods such as binary-gene typing or single-nucleo-
tide polymorphism (SNP)-typing to describe the patho-
gens in detail. In case of a suspected outbreak, other 
complementary data (e.g. epidemiological) are added 
as well. A recent review of MLVA typing at NIPH was 
recently published [45]. Other institutions in Norway 
have also published MLVA assays: the University of 
Bergen has published the first MLVA method for typ-
ing the fish pathogen Francisella noatunensis [46] and 
the Norwegian Defence Research Establishment (NDRE) 
has developed and evaluated an MLVA assay for Vibrio 
cholerae, which proved to be both fast (within 3–5 
hours) and highly discriminatory [47]. The Norwegian 
University of Science and Technology has developed 
and applied an MLVA assay for Streptococcus agalac-
tiae with promising results: a five-locus MLVA assay 
was considered to resolve a strain collection of 126 
S. agalactiae strains considerably better than multi-
locus sequence typing (MLST) and with less workload 
[48].
Sweden
The ease of standardisation and portability of data 
makes MLVA particularly useful for molecular epi-
demiology of zoonotic disease agents, where close 
collaboration between human and animal health agen-
cies is necessary. For example, all primary isolates 
of S. Typhimurium and monophasic S. Typhimurium 
4,[5],12:i:- found in animals and animal feed are 
routinely typed at the Swedish National Veterinary 
Institute (SVA), using the protocol recommended by the 
European Centre for Disease Prevention and Control 
(ECDC) [1, 2]. The same method is used for all clinical 
isolates at the Swedish Institute for Communicable 
Disease Control (SMI) and data are exchanged con-
tinuously to facilitate source attribution and outbreak 
investigation. The comparability of typing data is 
ensured by standardised nomenclature and analysis 
of an external panel of calibration strains [2] at both 
laboratories.
A similar SMI/SVA collaboration is active for verotoxin-
producing E. coli (VTEC) O157:H7, using a slightly modi-
fied version of the Centers for Disease Control and 
Prevention protocol developed by Hyytiä-Trees et al. 
[49]. At SVA, this method has recently been shown to 
offer comparable performance to PFGE typing for cattle 
isolates [50], while being substantially faster and less 
laborious. An ongoing research project is comparing 
clinical isolate profiles generated at SMI to those from 
isolates from periodical nationwide slaughterhouse 
prevalence studies on cattle and from sheep isolates. 
Again, analysis of a panel of isolates with sequenced 
loci was necessary to achieve harmonisation between 
laboratories: in this case, a certain amount of in-house 
optimisation was also necessary to avoid false nega-
tives due to multiplex PCR competition. 
The MLVA for Coxiella burnetii at SVA is based on the 
method by Arricau-Bouvery et al. [51]. In recent years, 
C. burnetii has been found on several farms in Sweden 
and by using this method, strains that are prevalent in 
the country during normal conditions as well as dur-
ing an outbreak can identified. An advantage of this 
method is that culturing is not required, which is time 
consuming and laborious for a biosaftey level (BSL) 3 
agent. This method also makes it easier for interna-
tional collaboration, since there is no need to send 
live bacteria between countries. For instance, C. bur-
netii cattle isolate DNA sent to the SVA by a European 
partner for an epidemiological study is currently being 
analysed.
In Sweden, there is an increasing trend of pathogenic 
and non-pathogenic Enterobacteriaceae producing 
extended-spectrum beta-lactamases (ESBL) and plas-
mid-mediated AmpC (pAmpC) in veterinary settings 
and food-producing animals. However, compared with 
the rest of Europe, the problem in Sweden is still very 
limited, with the exception of the high occurrence of 
pAmpC and ESBL producing E. coli in broilers [52]. SVA 
is therefore planning to use the extended Lindstedt et 
al. MLVA protocol [44] to study the genetic relatedness 
of ESBL- and pAmpC-producing E. coli among Swedish 
broilers, including imported breeding stocks, over 
time and through the production chain. Collaboration 
between SVA, SMI and the National Food Agency to 
compare ESBL-/pAmpC-producing E. coli of human, 
animal and food origin is also in the start-up phase. 
Furthermore, there are also plans to apply the protocol 
to study possible outbreaks of ESBL-/pAmpC-producing 
pathogens in veterinary settings.  The same method 
will also be used in an upcoming SVA/SMI collabora-
tive project for typing of non-O157 VTEC.
Conclusion
Europe has been very successful in developing and 
using the MLVA methodology: the amount of research 
and development into MLVA has been considerable 
for a large array of organisms (Table 1). The develop-
ment of the methodology within Europe is dynamic and 
assay updates are frequently published. The first step 
towards uniform standardisation at the European Union 
(EU) level has been taken with the online posting of 
the standard operating procedure for S. Typhimurium 
MLVA by ECDC [53]. This Euroroundup further shows 
that MLVA has become an important tool for scientific 
studies and as an aid in outbreak detection and source 
tracing in European countries. 
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As MLVA assays rely on the information gathered by 
genome sequencing, data available for use in method 
development, or improving exsisting protocols, is 
being published frequently. As of 17 December 2012, 
a total of 2,411 whole bacterial genomes were listed 
by the National Center for Biotechnology Information 
(NCBI) [54], where all sequences may be downloaded 
and examined for VNTR content. Thus, MLVA assay 
development can be performed regardless of access to 
in-house sequencing (although this is an advantage).   
The nature of MLVA makes it a practical system for 
rapid sharing and digital storing of results, as can be 
seen by the online databases that are already opera-
tional in Europe. This has been achieved in a relatively 
short time frame: a S. Typhimurium MLVA protocol was 
first published in 2004 [1] and by September 2011, 
standardised protocols were available in Europe [53]. 
In comparison, PFGE was first described in the early 
80s and it was not until 2004 that PulseNet Europe 
was established, using protocols standardised in the 
United States [55].  The modern methodology asso-
ciated with MLVA protocols makes MLVA a good can-
didate for integrated surveillance systems, where 
numerous types of data relating to, for example, strain 
genotypes, antibiotic resistance, virulence profiles, 
geographical information and patient/disease infor-
mation may be stored, combined and shared with the 
same ease.  What is needed is centralised concerted 
action at the EU level and it is a positive develop-
ment that ECDC is now integrating MLVA as part of the 
European Surveillance System (TESSy) [56].  This is an 
exciting development and it is hoped that more MLVA 
protocols will be integrated into TESSy in the future. 
Incorporation of MLVA will be beneficial in outbreak sit-
uations where the speed of data retrieval is paramount 
for source tracing and actions across international bor-
ders to end the outbreak.  
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